Sirpa A Tavakoli, Ondria C Gleason. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Antidepressive Agents, Second-Generation/adverse effectsAntidepressive Agents, Second-Generation/therapeutic useAnxiety Disorders/drug therapyAttention Deficit Disorder with Hyperactivity/drug therapyCentral Nervous System Stimulants/adverse effectsCentral Nervous System Stimulants/therapeutic useComorbidityCyclohexanols/adverse effectsCyclohexanols/therapeutic useDepressive Disorder/drug therapyDose-Response Relationship, DrugDrug Therapy, CombinationEpilepsy, Tonic-Clonic/chemically inducedFemaleHumansHypnotics and Sedatives/adverse effectsHypnotics and Sedatives/therapeutic useMethylphenidate/adverse effectsMethylphenidate/therapeutic useMiddle AgedPyridines/adverse effectsPyridines/therapeutic useVenlafaxine HydrochlorideZolpidem
Substances： See more » Antidepressive Agents, Second-GenerationCentral Nervous System StimulantsCyclohexanolsHypnotics and SedativesPyridinesMethylphenidateVenlafaxine HydrochlorideZolpidem
Year: 2003 PMID： 12724513 DOI： 10.1176/appi.psy.44.3.262
Source DB: PubMed Journal: Psychosomatics ISSN： 0033-3182 Impact factor: 2.386